| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.0077 | 0.9 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | -0.007 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.0081 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.0058 | 0.9 |